Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M185,440Revenue (TTM) $M52,759Net Margin (%)17.5Altman Z-Score3.4
Enterprise Value $M206,719EPS (TTM) $1.4Operating Margin %27.5Piotroski F-Score5
P/E(ttm)21.3Beneish M-Score-2.9Pre-tax Margin (%)24.0Higher ROA y-yN
Price/Book10.310-y EBITDA Growth Rate %2.2Quick Ratio0.8Cash flow > EarningsY
Price/Sales3.95-y EBITDA Growth Rate %1.2Current Ratio1.1Lower Leverage y-yY
Price/Free Cash Flow17.4y-y EBITDA Growth Rate %1.3ROA % (ttm)12.4Higher Current Ratio y-yN
Dividend Yield %3.7PEG18.8ROE % (ttm)48.2Less Shares Outstanding y-yY
Payout Ratio %77.0Shares Outstanding M6,818ROIC % (ttm)28.2Gross Margin Increase y-yN

Gurus Latest Trades with RHHBY

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
RHHBYKen Fisher 2016-09-30 Reduce$30.39 - $32.86
($31.56)
$ 27.20-14%Reduce -0.10%15,126,928
RHHBYKen Fisher 2016-06-30 Add0.01%$30.26 - $33.68
($31.82)
$ 27.20-15%Add 1.58%15,142,209
RHHBYKen Fisher 2016-03-31 Add0.02%$30.09 - $34.47
($31.91)
$ 27.20-15%Add 1.88%14,906,191
RHHBYKen Fisher 2015-12-31 Add0.01%$32.55 - $35.08
($33.69)
$ 27.20-19%Add 0.63%14,630,453
RHHBYKen Fisher 2015-09-30 Add0.02%$31.65 - $36.87
($34.69)
$ 27.20-22%Add 2.30%14,538,602
RHHBYKen Fisher 2015-06-30 Add0.8%$34.38 - $38.46
($36.09)
$ 27.20-25%Add 409.71%14,211,412
RHHBYKen Fisher 2015-03-31 Reduce$32.1 - $36.505
($34.06)
$ 27.20-20%Reduce -1.24%2,788,126
RHHBYKen Fisher 2014-12-31 Add0.07%$34.16 - $37.92
($36.33)
$ 27.20-25%Add 49.26%2,823,025
RHHBYKen Fisher 2014-06-30 Reduce-0.07%$35.42 - $38.07
($36.82)
$ 27.20-26%Reduce -49.71%1,813,443
RHHBYKen Fisher 2014-03-31 Add0.07%$18.14 - $38.17
($29.75)
$ 27.20-9%Add 99.00%1,803,070
RHHBYKen Fisher 2013-12-31 Reduce$31.96 - $35.24
($34.15)
$ 27.20-20%Reduce -0.26%1,812,112
RHHBYKen Fisher 2013-09-30 Add$30.66 - $33.77
($31.86)
$ 27.20-15%Add 0.28%1,816,868
RHHBYTweedy Browne 2013-06-30 Sold Out $28.92 - $32.98
($30.92)
$ 27.20-12%Sold Out0
RHHBYKen Fisher 2013-06-30 Add$28.92 - $32.98
($30.92)
$ 27.20-12%Add 0.90%1,811,804
RHHBYKen Fisher 2013-03-31 Add0.12%$25.62 - $29.3
($27.78)
$ 27.20-2%Add 634.57%1,795,722
RHHBYTweedy Browne 2012-12-31 Reduce$23.08 - $25.68
($24.54)
$ 27.2011%Reduce -3.04%120,548
RHHBYKen Fisher 2012-12-31 Reduce$23.08 - $25.68
($24.54)
$ 27.2011%Reduce -14.81%244,460
RHHBYTweedy Browne 2012-09-30 Reduce-0.03%$20.99 - $24.07
($22.5)
$ 27.2021%Reduce -24.31%124,328
RHHBYKen Fisher 2012-09-30 Reduce$20.99 - $24.07
($22.5)
$ 27.2021%Reduce -7.27%286,946
RHHBYVanguard Health Care Fund 2012-06-30 Add2.96%$19.43 - $23.14
($21.18)
$ 27.2028%Add 543.36%8,547,954
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

RHHBY is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


RHHBY: Insider Buys/Sells

Click Here for All Insider Trades.

No Insider Trades Found!

Quarterly/Annual Reports about RHHBY:

    News about RHHBY:

    Articles On GuruFocus.com
    Leith Wheeler Investment Funds 3rd Quarter Review Nov 01 2016 
    Roche, AbbVie: Venclyxto Receives Positive Opinion From Committee Oct 14 2016 
    Mairs and Power Buys Walt Disney, Exits Baxalta Sep 27 2016 
    Is Bristol-Myers Squibb Presenting an Opportunity? Sep 08 2016 
    Can Novartis Tide Over the Alcon Crisis? Aug 26 2016 
    Innovative Diagnostic and Therapeutic Products Seen at Roche Aug 22 2016 
    Siegfried Holdings, Held by Tweedy Browne, Way Undervalued Jul 22 2016 
    Roche Holdings Definitely Not a Lumbering Giant Jul 11 2016 
    Invesco Adds to Holdings in Investment, Financial Services Companies Jul 01 2016 
    Bearish Sentiment in Becton Dickinson's Stock Apr 27 2016 

    More From Other Websites
    Merck KGaA (MKGAF) Expands Distribution Deal with Roche Dec 02 2016
    Pfizer's Herceptin Biosimilar Meets Primary Endpoint in Study Dec 01 2016
    8:04 am Roche Hldg expands distribution alliance with the life science business of Merck KGaA (Dec 01 2016
    Roche expands distribution alliance with the life science business of Merck KGaA, Darmstadt, Germany... Dec 01 2016
    Pfizer's Herceptin biosimilar succeeds in key breast cancer study Nov 30 2016
    Epizyme Tazemetostat Gets Fast Track Designation in U.S. Nov 29 2016
    5 BioPharma Catalysts Expected Around Christmas Nov 27 2016
    Roche launches DISCOVERY 5-Plex procedure for cancer research applications Nov 21 2016
    Yes, It’s a Similar Label for Opdivo and Tecentriq in Lung Cancer Nov 21 2016
    Pharma Stock Roundup: Data Presented at ACR, Bristol-Myers Inks Immuno-Oncology Deal Nov 18 2016
    Pharma Balks at German Price Control (BAYRY, RHHBY) Nov 16 2016
    Amgen Files for Avastin Biosimilar; Repatha Data Positive Nov 16 2016
    Roche announces positive results for Actemra in phase III study Nov 13 2016
    Phase III GiACTA Study Shows Genentech’s Actemra® is Superior to Steroids Alone in Maintaining... Nov 12 2016
    Looking Abroad for Dividend Growth Nov 11 2016
    Prothena Stock Outplays Broader Biotechs On Key Parkinson's Study Nov 10 2016
    Mylan's Herceptin Copycat Progresses (MYL, RHHBY) Nov 10 2016
    FDA approves Roche's VENTANA ALK (D5F3) CDx Assay for use on the VENTANA BenchMark ULTRA system Nov 07 2016
    Roche launches new RNA HyperPrep product line Nov 07 2016
    Roche Hemophilia Drug Snagged by Bloodclot (RHHBY) Nov 05 2016

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)